Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 May 7;27(16):4531–4538. doi: 10.1158/1078-0432.CCR-20-4890

Figure 4.

Figure 4.

Validation of multi-hit TP53 in 112 TP53 aberrant patients with chronic lymphocytic leukemia following initiation of single-agent ibrutinib. (A) Overall survival and (B) progression-free survival in patients with single-hit (gray) and multi-hit (black striped) TP53. Overall survival and progression-free survival were significantly shorter in patients with multi-hit TP53.